CapVest Completes Majority Acquisition of Stada March 31, 2026 CapVest Partners LLP (“CapVest”), a leading global investment firm, today announces the completion of its acquisition of the majority stake in STADA Arzneimittel AG (“STADA” or the “Company”), a leading healthcare and pharmaceuticals company specializing in Consumer Healthcare, Generics and Specialty Pharmaceuticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260331987319/en/ Building on [...]
Bedford Blues chief: Champ Rugby clubs are investment opportunities March 31, 2026 When the RFU Council approved plans that would ringfence Prem Rugby for a number of years and create what many described as a franchise league, it is fair to say there were critics. And there still are, with many of them within the second-tier Champ. But Prem Rugby may not be a closed shop forever, [...]
Awful April: brace for a wave of stealth tax rises March 31, 2026 April is upon us and the new tax year will usher in a range of tax hikes, despite the absence of any headline rate rises, with frozen thresholds, shrinking allowances and tighter reliefs set to hit families, workers and savers. The harsh impact will also be felt as Brits are hit with a wave of [...]
CMA launches investigation into Microsoft amid cloud contract crackdown March 31, 2026 The UK’s competition watchdog has launched a new probe into Microsoft’s business software ecosystem, as part of a wider push to loosen the grip of Big Tech on cloud, and boost competition for British firms. The Competition and Markets Authority (CMA) said it will open a strategic market status investigation in Microsoft’s suite, including Windows, [...]
Andy Haldane: My mission to ignite Britain’s animal spirits March 31, 2026 As the Bank of England’s chief economist, Andy Haldane had a front row seat to the maladies of UK’s sluggish economy. After a four-year stint running the RSA, he is back as president of the British Chambers of Commerce, and tells Ali Lyon business is still taxed mindlessly, over regulated, and far too risk averse. [...]
Charging for museums will erode Britain’s soft power March 31, 2026 Ending free museum access would see some of Britain's most coveted institutions fade to irrelevance, writes Benji Wiedemann.
Reeves summons supermarket bosses again after snub March 31, 2026 Rachel Reeves has summoned supermarket bosses for a Downing Street meeting on Wednesday after being snubbed last week. The new meeting will be attended by executives at Sainsbury’s and Tesco but bosses at Asda, Aldi and John Lewis will miss out, supposedly due to diary clashes. The Chancellor hastily invited grocery executives to a meeting [...]
Unilever freezes hiring as Iran war poses ‘significant challenges’ March 31, 2026 FTSE 100 giant Unilever has placed a global freeze on hiring for at least three months as the Iran war wreaks havoc on global supply chains and fuel prices. The London-based business, which owns Dove soap and Hellman’s mayonnaise, told staff the ban on hiring will affect “all levels” of recruitment and was taken in [...]
Blackrock mulls a move to HSBC’s Canary Wharf tower March 31, 2026 Blackrock is mulling a move to HSBC’s Canary Wharf skyscraper with the site one of a number of locations viewed by the firm as it scouts for a new London headquarters. The world’s largest asset manager has taken a look at the 8 Canada Square tower, which HSBC is set to vacate next year. But [...]
Alfasigma Reports Solid Performance in 2025 Supported by Double-Digit Revenue Growth in key strategic brands in Immunology (+17%1), Gastroenterology (+15%), Vascular (+10%), and Consumer Healthcare expansion portfolio in international markets March 31, 2026 Revenues of €1.8 billion (-4% versus PY) driven by solid performance across key therapeutic areas and global markets, partially offset by Ocaliva® withdrawal impact. Adjusted EBITDA2 of €350 million (-18% versus PY) underpinned by streamlined operational efficiencies and operating model evolution. Like-for-like Revenues up 7%, and EBITDA up 20%, adjusted for voluntarily withdrawal of Ocaliva® from US market. Marketing application under EMA review for the use of Jyseleca® in a new indication of axial spondyloarthritis (axSpA), a chronic inflammatory arthritis, to address unmet patient needs, submitted following the reporting period. Following the reporting period, agreement with GSK plc for worldwide exclusive rights to develop, manufacture and commercialise linerixibat; subsequently granted FDA approval for the US market (March 2026).